Special Drug Use-results survey for long term administration of Reminyl 4mg/8mg/12mg Tablets, 4mg/8mg/12mg OD Tablets, 4mg/mL Oral Solution

Special Drug Use-results survey for long term administration of Reminyl 4mg/8mg/12mg Tablets, 4mg/8mg/12mg OD Tablets, 4mg/mL Oral Solution - Special Drug Use-results survey for long term administration of Reminyl 4mg/8mg/12mg Tablets, 4mg/8mg/12mg OD Tablets, 4mg/mL Oral Solution

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017151

Enrollment

600

Registered

2015-04-20

Start date

2011-04-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderately severe dementia of the Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with mild to moderately severe dementia of the Alzheimer's type who was admnistered Reminyl for the first time

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety (Adverse Drug Reactions) Efficacy (Mini-Mental State Examination, Clinical Global Impression-Improvement scale, Medication Satisfaction Questionnaire of caretaker)	—

Countries

Japan

Contacts

Public ContactHirokazu Shirai

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

hshirai3@ITS.JNJ.com03-4411-5951

Outcome results